Business
Directors Dealings
Directors Dealings.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 4113Q Faron Pharmaceuticals Oy 11 September 2017 \n\n \n \n \nFaron Pharmaceuticals Oy\n\n(\"Faron\" or the \"Company\")\n \nDirector's Dealing\n \n \nTURKU - FINLAND, 11 September 2017 - Faron Pharmaceuticals Ltd (\"Faron\") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 11 September 2017 it was notified that on 8 September 2017 Dr Jonathan Knowles, a Non-Executive Director of the Company, acquired 63,000 ordinary shares in Faron at a price of 725 pence per ordinary share. Following the purchase, Dr Knowles holds 110,712 ordinary shares in the Company.\n \nThe notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.\n \n \n\n\n\n\nNotification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014\n\n\n\n\n1\n\n\nDetails of the person discharging managerial responsibilities/person closely associated\n\n\n\n\na.\n\n\nName\n\n\nJonathan Knowles \n \n\n\n\n\n2\n\n\nReason for notification\n\n\n \n \n \n\n\n\n\na.\n\n\nPosition/Status\n\n\nPerson discharging managerial responsibilities\n \nDirector\n\n\n\n\nb.\n\n\nInitial notification/\nAmendment\n\n\nInitial Notification\n\n\n\n\n3\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na.\n\n\nName\n\n\nFaron Pharmaceuticals Oy \n\n\n\n\nb.\n\n\n...